TG Therapeutics (TGTX) PT Jumps To $39 At Ladenburg After AACR Data Presentation
Tweet Send to a Friend
Ladenburg Thalmann analyst Matthew Kaplan reiterated a Buy rating and raised his price target to $39 from $27on TG Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
